|
1
|
Korman AJ, Peggs KS and Allison JP:
Checkpoint blockade in cancer immunotherapy. Adv Immunol.
90:297–339. 2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chowdhury PS, Chamoto K and Honjo T:
Combination therapy strategies for improving PD-1 blockade
efficacy: A new era in cancer immunotherapy. J Intern Med.
283:110–120. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shi X, Li CW, Tan LC, Wen SS, Liao T,
Zhang Y, Chen TZ, Ma B, Yu PC, Lu ZW, et al: Immune co-inhibitory
receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary
thyroid cancers: A large cohort study. J Clin Endocrinol Metab.
106:120–132. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ou X, Ma Q, Yin W, Ma X and He Z:
CRISPR/Cas9 gene-editing in cancer immunotherapy: Promoting the
present revolution in cancer therapy and exploring more. Front Cell
Dev Biol. 9(674467)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pettitt D, Arshad Z, Smith J, Stanic T,
Holländer G and Brindley D: CAR-T cells: A systematic review and
mixed methods analysis of the clinical trial landscape. Mol Ther.
26:342–353. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li S, Zhang Z, Lai WF, Cui L and Zhu X:
How to overcome the side effects of tumor immunotherapy. Biomed
Pharmacother. 130(110639)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Medler TR, Cotechini T and Coussens LM:
Immune response to cancer therapy: Mounting an effective antitumor
response and mechanisms of resistance. Trends Cancer. 1:66–75.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li Q, Carr AL, Donald EJ, Skitzki JJ,
Okuyama R, Stoolman LM and Chang AE: Synergistic effects of IL-12
and IL-18 in skewing tumor-reactive T-cell responses towards a type
1 pattern. Cancer Res. 65:1063–1070. 2005.PubMed/NCBI
|
|
11
|
Mortara L, Balza E, Bruno A, Poggi A,
Orecchia P and Carnemolla B: Anti-cancer therapies employing IL-2
cytokine tumor targeting: Contribution of innate, adaptive and
immunosuppressive cells in the anti-tumor efficacy. Front Immunol.
9(2905)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dubensky TW Jr and Reed SG: Adjuvants for
cancer vaccines. Semun Immunol. 22:155–161. 2010.PubMed/NCBI View Article : Google Scholar : Mantia-Smaldone GM
and Chu CS: A review of dendritic cell therapy for cancer: Progress
and challenges. BioDrug 27, 453-468, 2013.
|
|
13
|
Higgins JP, Bernstein MB and Hodge JW:
Enhancing immune responses to tumor-associated antigens. Cancer
Biol Ther 8: 1440-1449, 2009; Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tang K, Wu YH, Song Y and Yu B:
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials
for cancer immunotherapy. J Hematol Oncol. 14(68)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yu B, Kusmartsev S, Cheng F, Paolini M,
Nefedova Y, Sotomayor E and Gabrilovich D: Effective combination of
chemotherapy and dendritic cell administration for the treatment of
advanced-stage experimental breast cancer. Clin Cancer Res.
9:285–294. 2003.PubMed/NCBI
|
|
16
|
Teitz-Tennenbaum S, Li Q, Davis MA,
Wilder-Romans K, Hoff J, Li M and Chang AE: Radiotherapy combined
with intratumoral dendritic cell vaccination enhances the
therapeutic efficacy of adoptive T-cell transfer. J Immunother.
32:602–612. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Belderbos RA, Aerts JGJV and Vroman H:
Enhancing dendritic cell therapy in solid tumors with
immunomodulating conventional treatment. Mol Ther Oncolytics.
13:67–81. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kawano M, Tanaka K, Itonaga I, Iwasaki T,
Miyazaki M, Ikeda S and Tsumura H: Dendritic cells combined with
doxorubicin induces immunogenic cell death and exhibits antitumor
effects for osteosarcoma. Oncol Lett. 11:2169–2175. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bai R, Chen N, Li L, Du N, Bai L, Lv Z,
Tian H and Cui J: Mechanisms of cancer resistance to immunotherapy.
Front Oncol. 10(1290)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Santos PM and Butterfield LH: Dendritic
cell-based cancer vaccines. J Immunol. 200:443–449. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lee C, Lee M and Rhee I: Distinct features
of dendritic cell-based immunotherapy as cancer vaccines. Clin Exp
Vaccine Res. 7:16–23. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Giovanelli P, Sandoval TA and
Cubillos-Ruiz JR: Dendritic cell metabolism and function in tumors.
Trends Immunol. 40:699–718. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Steinman RM and Nussenzweig MC: Dendritic
cells: Features and functions. Immunol Rev. 53:127–147.
1980.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gardner A, de Mingo Pulido Á and Ruffell
B: Dendritic cells and their role in immunotherapy. Front Immunol.
11(924)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Satthaporn S, Robins A, Vassanasiri W,
El-Sheemy M, Jibril JA, Clark D, Valerio D and Eremin O: Dendritic
cells are dysfunctional in patients with operable breast cancer.
Cancer Immunol Immunother. 53:510–518. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gallois A and Bhardwaj N: Dendritic
cell-targeted approaches to modulate immune dysfunction in the
tumor microenvironment. Front Immunol. 4(436)2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mastelic-Gavillet B, Sarivalasis A, Lozano
LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P,
Derrè L, Coukos G, et al: Quantitative and qualitative impairments
in dendritic cell subsets of patients with ovarian or prostate
cancer. Eur J Cancer. 135:173–182. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bandola-Simon J and Roche PA: Dysfunction
of antigen processing and presentation by dendritic cells in
cancer. Mol Immunol. 113:31–37. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yang L and Carbone DP: Tumor-host immune
interactions and dendritic cell dysfunction. Adv Cancer Res.
92:13–27. 2004.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Restifo NP, Dudley ME and Rosenberg SA:
Adoptive immunotherapy for cancer: Harnessing the T cell response.
Nat Rev Immunol. 12:269–281. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Shevchenko JA, Khristin AA, Kurilin VV,
Kuznetsova MS, Blinova DD, Starostina NM, Sidorov SV and Sennikov
SV: Autologous dendritic cells and activated cytotoxic T-cells as
combination therapy for breast cancer. Oncol Rep. 43:671–680.
2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ophir E, Bobisse S, Coukos G, Harari A and
Kandalaft LE: Personalized approaches to active immunotherapy in
cancer. Biochim Biophys Acta. 1865:72–82. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sennikov SV, Khantakova JN, Kulikova EV,
Obleukhova IA and Shevchenko JA: Modern strategies and capabilities
for activation of the immune response against tumor cells. Tumour
Biol. 39(1010428317698380)2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Brossart P, Schneider A, Dill P, Schammann
T, Grünebach F, Wirths S, Kanz L, Bühring HJ and Brugger W: The
epithelial tumor antigen MUC1 is expressed in hematological
malignancies and is recognized by MUC1-specific cytotoxic
T-lymphocytes. Cancer Res. 61:6846–6850. 2001.PubMed/NCBI
|
|
35
|
Cloosen S, Arnold J, Thio M, Bos GM,
Kyewski B and Germeraad WT: Expression of tumor-associated
differentiation antigens, MUC1 glycoforms and CEA, in human thymic
epithelial cells: Implications for self-tolerance and tumor
therapy. Cancer Res. 67:3919–3926. 2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Baeuerle PA and Gires O: .: EpCAM (CD326)
finding its role in cancer. Br J Cancer. 96:417–423.
2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Criscitiello C: Tumor-associated antigens
in breast cancer. Breast Care (Basel). 7:262–266. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sennikov SV, Shevchenko JA, Kurilin VV,
Khantakova JN, Lopatnikova JA, Gavrilova EV, Maksyutov RA, Bakulina
AY, Sidorov SV, Khristin AA and Maksyutov AZ: Induction of an
antitumor response using dendritic cells transfected with DNA
constructs encoding the HLA-A*02:01-restricted epitopes
of tumor-associated antigens in culture of mononuclear cells of
breast cancer patients. Immunol Res. 64:171–180. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kuznetsova M, Lopatnikova J, Shevchenko J,
Silkov A, Maksyutov A and Sennikov S: Cytotoxic activity and memory
T cell subset distribution of in vitro-stimulated CD8+ T cells
specific for HER2/neu epitopes. Front Immunol.
10(1017)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sennikov SV, Maksyutov AZ, Maksyutov RA,
Bakulina AY, Gavrilova EV, Kurilin VV, Lopatnikova YA, Shevchenko
YA, Obleukhova IA, Kulikova EV, et al: The polyepitope antitumor
vaccine construct containing epitopes of tumor-associated antigens,
pharmaceutical composition, and its application to elicit the
specific antitumor immune response. RF Patent 2684235. Filed
November 29, 2016; issued April 4, 2019.
|
|
41
|
Lundegaard C, Lamberth K, Harndahl M, Buus
S, Lund O and Nielsen M: NetMHC-3.0: Accurate web accessible
predictions of human, mouse and monkey MHC class I affinities for
peptides of length 8-11. Nucleic Acids Res. 36 (Web Server
Issue):W509–W512. 2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Antonets DV and Maksiutov AZ: TEpredict:
Software for T-cell epitope prediction. Mol Biol. 44:119–127.
2010.PubMed/NCBI
|
|
43
|
Böyum A: Separation of leukocytes from
blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl.
97(7)1968.PubMed/NCBI
|
|
44
|
Rufer N, Brümmendorf TH, Kolvraa S,
Bischoff C, Christensen K, Wadsworth L, Schulzer M and Lansdorp PM:
Telomere fluorescence measurements in granulocytes and T lymphocyte
subsets point to a high turnover of hematopoietic stem cells and
memory T cells in early childhood. J Exp Med. 190:157–167.
1999.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Arrigucci R, Bushkin Y, Radford F, Lakehal
K, Vir P, Pine R, Martin D, Sugarman J, Zhao Y, Yap GS, et al:
FISH-flow, a protocol for the concurrent detection of mRNA and
protein in single cells using fluorescence in situ hybridization
and flow cytometry. Nat Protoc. 12:1245–1260. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Schneider T, Hoffmann H, Dienemann H,
Schnabel PA, Enk AH, Ring S and Mahnke K: Non-small cell lung
cancer induces an immunosuppressive phenotype of dendritic cells in
tumor microenvironment by upregulating B7-H3. J Thorac Oncol.
6:1162–1168. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hu Y, Qi W, Sun L, Zhou H, Zhou B and Yang
Z: Effect of TGF-β1 on blood CD4+CD25 high regulatory T cell
proliferation and Foxp3 expression during non-small cell lung
cancer blood metastasis. Exp Ther Med. 16:1403–1410.
2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Obleukhova I, Kiryishina N, Falaleeva S,
Lopatnikova J, Kurilin V, Kozlov V, Vitsin A, Cherkasov A, Kulikova
E and Sennikov S: Use of antigen-primed dendritic cells for
inducing antitumor immune responses in vitro in patients with
non-small cell lung cancer. Oncol Lett. 15:1297–1306.
2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Fiala O, Šorejs O, Šustr J and Fínek J:
Side effects and efficacy of immunotherapy. Klin Onkol. 33:8–10.
2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Blidner AG, Choi J, Cooksley T, Dougan M,
Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, et
al: Cancer immunotherapy-related adverse events: Causes and
challenges. Support Care Cancer. 28:6111–6117. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kichloo A, Albosta M, Dahiya D, Guidi JC,
Aljadah M, Singh J, Shaka H, Wani F, Kumar A and Lekkala M:
Systemic adverse effects and toxicities associated with
immunotherapy: A review. World J Clin Oncol. 12:150–163.
2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Boudewijns S, Westdorp H, Koornstra RH,
Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de
Vries IJ, Gerritsen WR and Bol KF: Immune-related adverse events of
dendritic cell vaccination correlate with immunologic and clinical
outcome in stage III and IV melanoma patients. J Immunother.
39:241–248. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Chen C, Ma YH, Zhang YT, Zhang F, Zhou N,
Wang X, Liu T and Li YM: Effect of dendritic cell-based
immunotherapy on hepatocellular carcinoma: A systematic review and
meta-analysis. Cytotherapy. 20:975–989. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Mellman I and Steinman RM: Dendritic
cells: Specialized and regulated antigen processing machines. Cell.
106:255–258. 2001.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Blankenstein T, Coulie PG, Gilboa E and
Jaffee EM: The determinants of tumour immunogenicity. Nat Rev
Cancer. 12:307–313. 2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Picard E, Verschoor CP, Ma GW and Pawelec
G: Relationships between immune landscapes, genetic subtypes and
responses to immunotherapy in colorectal cancer. Front Immunol.
11(369)2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
de Vries NL, Swets M, Vahrmeijer AL,
Hokland M and Kuppen PJ: The immunogenicity of colorectal cancer in
relation to tumor development and treatment. Int J Mol Sci.
17(1030)2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Zhou J, Yu X, Hou L, Zhao J, Zhou F, Chu
X, Wu Y, Zhou C and Su C: Epidermal growth factor receptor tyrosine
kinase inhibitor remodels tumor microenvironment by upregulating
LAG-3 in advanced non-small-cell lung cancer. Lung Cancer.
153:143–149. 2021.PubMed/NCBI View Article : Google Scholar
|
